- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- February 2025
- 148 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 250 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- February 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 133 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 133 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 130 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Drug Pipelines
- April 2024
- 180 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Clinical Trials
- April 2024
- 85 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Report
- August 2024
- 150 Pages
Global
From €2651EUR$2,789USD£2,227GBP
- Report
- November 2022
- 154 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Report
- June 2020
- 753 Pages
Global
From €3137EUR$3,300USD£2,636GBP
- Report
- August 2022
- 115 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Drug Pipelines
- January 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- January 2024
- 90 Pages
Global
From €1901EUR$2,000USD£1,597GBP

Pazopanib is an oncology drug used to treat certain types of cancer. It is a tyrosine kinase inhibitor, meaning it works by blocking the action of certain enzymes that are involved in the growth and spread of cancer cells. Pazopanib is used to treat advanced renal cell carcinoma, a type of kidney cancer, and advanced soft tissue sarcoma, a type of cancer that affects the connective tissues. It is also used to treat other types of cancer, such as ovarian cancer and thyroid cancer.
Pazopanib is available in tablet form and is taken orally. It is usually taken once daily, with or without food. Common side effects of pazopanib include nausea, vomiting, diarrhea, fatigue, and hair loss.
Some companies in the pazopanib market include GlaxoSmithKline, Novartis, and Pfizer. Show Less Read more